Related Experiment Videos
Circulating anticoagulant against factor XI in psoriasis
Journal of Medicine
|January 1, 1982
Summary
A rare acquired anticoagulant targeting Factor XI was identified in a patient with psoriasis. This Factor XI inhibitor did not cause bleeding or thrombosis despite persistent activity over 15 months.
Area of Science:
- Hematology
- Immunology
- Dermatology
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Acquired anticoagulants are rare autoimmune disorders.
- Systemic lupus erythematosus can be associated with anticoagulants.
Observation:
- A 56-year-old man with psoriasis presented with an unexplained Factor XI inhibitor.
- The anticoagulant activity against Factor XI persisted for over 15 months.
- The inhibitor's activity was not enhanced by normal plasma addition.
Findings:
- Low Factor IX activity was noted but not fully explained by the Factor XI inhibitor.
- The acquired anticoagulant did not lead to bleeding complications.
- The patient did not experience myocardial infarction despite the anticoagulant.
Implications:
- This case highlights a rare acquired Factor XI inhibitor in a patient with psoriasis.
- The clinical significance of Factor XI inhibitors without associated bleeding or thrombosis requires further investigation.
- Understanding the immunopathogenesis of such inhibitors may offer new therapeutic insights.